Improving the metabolic disorder of intestinal flora by inhibiting the TLR4/NF-κB signal pathway, significantly reducing the ratio of non-Michter/Bacteroides, and inhibiting the inflammatory cascade reaction. Here, NFKB1 is linked to metabolic disease.